Clinical Trial Update: Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) [Phase 3]

View source ↗

Summary

This update reports the completion of a Phase 3 trial evaluating recombinant human thrombopoietin in combination with rituximab for immune thrombocytopenia (ITP…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rituximab (rituximab)
• recombinant human thrombopoietin (recombinant human thrombopoietin)

Snippet

Sponsor: Ming Hou | Conditions: Purpura, Idiopathic Thrombocytopenic Purpura | Phase 3 | Status: COMPLETED